Endometrial Cancer Molecular Risk Stratification is Equally Prognostic for Endometrioid Ovarian Carcinoma
- 15 October 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (20) , 5400-5410
Abstract
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a “one-size-fits-all” approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features with its endometrial counterpart, we sought to investigate The Cancer Genome Atlas–inspired endometrial carcinoma (EC) molecular subtyping in a cohort of ENOC. Experimental Design: IHC and mutation biomarkers were used to segregate 511 ENOC tumors into four EC-inspired molecular subtypes: low-risk POLE mutant (POLEmut), moderate-risk mismatch repair deficient (MMRd), high-risk p53 abnormal (p53abn), and moderate-risk with no specific molecular profile (NSMP). Survival analysis with established clinicopathologic and subtype-specific features was performed. Results: A total of 3.5% of cases were POLEmut, 13.7% MMRd, 9.6% p53abn, and 73.2% NSMP, each showing distinct outcomes (P < 0.001) and survival similar to observations in EC. Median OS was 18.1 years in NSMP, 12.3 years in MMRd, 4.7 years in p53abn, and not reached for POLEmut cases. Subtypes were independent of stage, grade, and residual disease in multivariate analysis. Conclusions: EC-inspired molecular classification provides independent prognostic information in ENOC. Our findings support investigating molecular subtype–specific management recommendations for patients with ENOC; for example, subtypes may provide guidance when fertility-sparing treatment is desired. Similarities between ENOC and EC suggest that patients with ENOC may benefit from management strategies applied to EC and the opportunity to study those in umbrella trials.Keywords
All Related Versions
Funding Information
- Canadian Ovarian Cancer Research Consortium's COEUR
- Terry Fox Research Institute
- Centre Hospitalier de l'Université de Montréal
- Terry Fox Research Institute's pan-Canadian Ovarian Cancer study
- BC Cancer Foundation
This publication has 50 references indexed in Scilit:
- Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid CarcinomaInternational Journal of Gynecological Cancer, 2015
- Detection of DNA mismatch repair (MMR) deficiencies by immunohistochemistry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomasGynecologic Oncology, 2015
- Sequence Artifacts in DNA from Formalin-Fixed Tissues: Causes and Strategies for MinimizationClinical Chemistry, 2015
- Type I and II Endometrial Cancers: Have They Different Risk Factors?Journal of Clinical Oncology, 2013
- Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profilesLaboratory Investigation, 2013
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosisEuropean Journal of Cancer, 2013
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Differences in Tumor Type in Low-stage Versus High-stage Ovarian CarcinomasInternational Journal of Gynecological Pathology, 2010
- Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker StudiesPLOS Medicine, 2008